{"id":918369,"date":"2025-12-10T09:06:05","date_gmt":"2025-12-10T14:06:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\/"},"modified":"2025-12-10T09:06:05","modified_gmt":"2025-12-10T14:06:05","slug":"aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\/","title":{"rendered":"AIM ImmunoTech Announces Release of the Next CEO Corner Segment"},"content":{"rendered":"<h2>\nTom Equels, CEO of AIM ImmunoTech, discusses the unmet need and driving Ampligen forward in pancreatic cancer<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"justify\">OCALA, Fla., Dec.  10, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DPHkFJD-jodeWRaDBuOiuvhSjSznheh0D07PzO3h0k8IjLMtDCCAfDeX5ooUDxeN9CTJ6KbHiYmA76SwW8XWuFSEC9sVZo-4QT9-wEV4vZg=\" rel=\"nofollow\" target=\"_blank\"><strong>AIM ImmunoTech Inc.<\/strong><\/a><strong> (NYSE American: AIM)\u00a0<\/strong>(\u201cAIM\u201d or the \u201cCompany\u201d) today announced the next\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-EKu6MRfvRSUnv08Bft28i4qn_raQn7S_5402V84u4MZyplzDax-iKWfsiBM-8psn5SPdR3PqxPxiyAc11zgsvGOq4VV3hqe0ryG1TH0oMs=\" rel=\"nofollow\" target=\"_blank\">CEO Corner<\/a>\u00a0segment has been published on the Company\u2019s website.<\/p>\n<p align=\"justify\">In this latest CEO Corner segment, AIM Chief Executive Officer Thomas Equels discusses the unmet need in pancreatic cancer and the Company\u2019s lead program, Ampligen<sup>\u00ae<\/sup> (rintatolimod), and its ongoing evaluation in the DURIPANC Phase 1b\/2 clinical trial in combination with AstraZeneca\u2019s Imfinzi<sup>\u00ae<\/sup> (durvalumab).<\/p>\n<p align=\"justify\">The CEO Corner segment is now available\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Tsbz0s-unz7sAXbuvb1071KpwRY2Ni-KPPWsirJ3aaVfxZMWwJwkpigbFknkkydf4jit9fRDq6jwmvazjdkPEQ==\" rel=\"nofollow\" target=\"_blank\">here<\/a>.<\/p>\n<p>\n        <strong>About AIM ImmunoTech Inc.<\/strong><br \/>\n        \n      <\/p>\n<p align=\"justify\">AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company\u2019s lead product is a first-in-class investigational drug called Ampligen<sup>\u00ae<\/sup>\u00a0(rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.<\/p>\n<p>For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4dhfVOqWhKMqWdX5LLk3QwpBrVfHZVVLCc6Dk8k7kyEdpVYGB8MMOCswnIDcbMbQjZVF9rgEv25_AKCjOqWbXA==\" rel=\"nofollow\" target=\"_blank\">aimimmuno.com<\/a>\u00a0and connect with the Company on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vQf9KQaAc6aRsDxhwAtvfk6_nu9rrs7nJT_x21s7USXkwrYTrw2xLYuqODGECV7sPopftvRlC5sSyNtUUWHUPA==\" rel=\"nofollow\" target=\"_blank\">X<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1PzpTSW0EPO_2KKxCh4osQxr__6xUEZ67MaV9Co_jjr-jvERPJ_z73k44HlDnPRE9doQiB-3bK-QBAE-vnZ5Ixhr1M4KvPyfdqW8xPXMQsY28ST72gHnYIayCg2T64WL\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>, and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hIJcXAASqJlBoMYAKNxNJN93TKV0pLuM7QmVB48L4xOehB2L4sbRWbcX9V1xuq-EeZBfSkYMnMzcYs_SA9rluOhNfjk60mg-1s0prHxpgXA=\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a>.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5OTc2MSM3MzE0NTcxIzIwMjMxNjQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjI5ZDRlMGItZDBiOS00YmYwLWJlNDUtNzBkOWI5NGQ4ZjYzLTEwMzQ3MzUtMjAyNS0xMi0xMC1lbg==\/tiny\/AIM-ImmunoTech-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Investor Contact:\r\n\r\nJTC Team, LLC\r\nJenene Thomas\r\n908.824.0775\r\nAIM@jtcir.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Tom Equels, CEO of AIM ImmunoTech, discusses the unmet need and driving Ampligen forward in pancreatic cancer OCALA, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) &#8212; AIM ImmunoTech Inc. (NYSE American: AIM)\u00a0(\u201cAIM\u201d or the \u201cCompany\u201d) today announced the next\u00a0CEO Corner\u00a0segment has been published on the Company\u2019s website. In this latest CEO Corner segment, AIM Chief Executive Officer Thomas Equels discusses the unmet need in pancreatic cancer and the Company\u2019s lead program, Ampligen\u00ae (rintatolimod), and its ongoing evaluation in the DURIPANC Phase 1b\/2 clinical trial in combination with AstraZeneca\u2019s Imfinzi\u00ae (durvalumab). The CEO Corner segment is now available\u00a0here. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AIM ImmunoTech Announces Release of the Next CEO Corner Segment&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-918369","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AIM ImmunoTech Announces Release of the Next CEO Corner Segment - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AIM ImmunoTech Announces Release of the Next CEO Corner Segment - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Tom Equels, CEO of AIM ImmunoTech, discusses the unmet need and driving Ampligen forward in pancreatic cancer OCALA, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) &#8212; AIM ImmunoTech Inc. (NYSE American: AIM)\u00a0(\u201cAIM\u201d or the \u201cCompany\u201d) today announced the next\u00a0CEO Corner\u00a0segment has been published on the Company\u2019s website. In this latest CEO Corner segment, AIM Chief Executive Officer Thomas Equels discusses the unmet need in pancreatic cancer and the Company\u2019s lead program, Ampligen\u00ae (rintatolimod), and its ongoing evaluation in the DURIPANC Phase 1b\/2 clinical trial in combination with AstraZeneca\u2019s Imfinzi\u00ae (durvalumab). The CEO Corner segment is now available\u00a0here. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of &hellip; Continue reading &quot;AIM ImmunoTech Announces Release of the Next CEO Corner Segment&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-10T14:06:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5OTc2MSM3MzE0NTcxIzIwMjMxNjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AIM ImmunoTech Announces Release of the Next CEO Corner Segment\",\"datePublished\":\"2025-12-10T14:06:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\\\/\"},\"wordCount\":200,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5OTc2MSM3MzE0NTcxIzIwMjMxNjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\\\/\",\"name\":\"AIM ImmunoTech Announces Release of the Next CEO Corner Segment - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5OTc2MSM3MzE0NTcxIzIwMjMxNjQ=\",\"datePublished\":\"2025-12-10T14:06:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5OTc2MSM3MzE0NTcxIzIwMjMxNjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU5OTc2MSM3MzE0NTcxIzIwMjMxNjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AIM ImmunoTech Announces Release of the Next CEO Corner Segment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AIM ImmunoTech Announces Release of the Next CEO Corner Segment - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\/","og_locale":"en_US","og_type":"article","og_title":"AIM ImmunoTech Announces Release of the Next CEO Corner Segment - Market Newsdesk","og_description":"Tom Equels, CEO of AIM ImmunoTech, discusses the unmet need and driving Ampligen forward in pancreatic cancer OCALA, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) &#8212; AIM ImmunoTech Inc. (NYSE American: AIM)\u00a0(\u201cAIM\u201d or the \u201cCompany\u201d) today announced the next\u00a0CEO Corner\u00a0segment has been published on the Company\u2019s website. In this latest CEO Corner segment, AIM Chief Executive Officer Thomas Equels discusses the unmet need in pancreatic cancer and the Company\u2019s lead program, Ampligen\u00ae (rintatolimod), and its ongoing evaluation in the DURIPANC Phase 1b\/2 clinical trial in combination with AstraZeneca\u2019s Imfinzi\u00ae (durvalumab). The CEO Corner segment is now available\u00a0here. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of &hellip; Continue reading \"AIM ImmunoTech Announces Release of the Next CEO Corner Segment\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-10T14:06:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5OTc2MSM3MzE0NTcxIzIwMjMxNjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AIM ImmunoTech Announces Release of the Next CEO Corner Segment","datePublished":"2025-12-10T14:06:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\/"},"wordCount":200,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5OTc2MSM3MzE0NTcxIzIwMjMxNjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\/","name":"AIM ImmunoTech Announces Release of the Next CEO Corner Segment - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5OTc2MSM3MzE0NTcxIzIwMjMxNjQ=","datePublished":"2025-12-10T14:06:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5OTc2MSM3MzE0NTcxIzIwMjMxNjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU5OTc2MSM3MzE0NTcxIzIwMjMxNjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aim-immunotech-announces-release-of-the-next-ceo-corner-segment-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AIM ImmunoTech Announces Release of the Next CEO Corner Segment"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/918369","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=918369"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/918369\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=918369"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=918369"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=918369"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}